DF/HCC Pipelines in Oncology: Agios

Thursday, March 20, 2014 at 12:30pm to 2:00pm

Register for this event

Agios is dedicated to the development of metabolic inhibitors/therapeutic agents, such as AG-221 (IDH2 inhibitor), AG-120 (IDH1 inhibitor) AG-348 (pyruvate kinase R activator), as well as other candidate metabolic cancer targets.
 
Visiting from Agios will be Samuel Agresta, MD, MPH & TM/TR, Senior Director and Head of Clinical Development. Dr. Agresta will be meeting with investigators at MGH in the morning and DFCI in the afternoon. If you are interested in a small group or 1:1 meeting with Dr. Agresta, please write to Andrea Talis (MGH), or Deborah Goff (DFCI). 

Lunch will be provided at DFCI for the seminar

Subscribe
Event Type

Clinical Research

Website

http://www.dfhcc.harvard.edu/member-r...

Event Contact Name

Deborah Goff

Event Contact Email

Deborah_Goff@dfci.harvard.edu

Recent Activity


NCI CCC